Literature DB >> 15514560

Recurrent respiratory papillomatosis: a longitudinal study comparing severity associated with human papilloma viral types 6 and 11 and other risk factors in a large pediatric population.

Brian J Wiatrak1, Deborah W Wiatrak, Thomas R Broker, Linda Lewis.   

Abstract

OBJECTIVES/HYPOTHESIS: A database was developed for prospective, longitudinal study of recurrent respiratory papillomatosis (RRP) in a large population of pediatric patients. Data recorded for each patient included epidemiological factors, human papilloma virus (HPV) type, clinical course, staged severity of disease at each surgical intervention, and frequency of surgical intervention. The study hypothesizes that patients with HPV type 11 (HPV-11) and patients younger than 3 years of age at diagnosis are at risk for more aggressive and extensive disease. STUDY
DESIGN: The 10-year prospective epidemiological study used disease staging for each patient with an original scoring system. Severity scores were updated at each surgical procedure.
METHODS: Parents of children with RRP referred to the authors' hospital completed a detailed epidemiological questionnaire at the initial visit or at the first return visit after the study began. At the first endoscopic debridement after study enrollment, tissue was obtained and submitted for HPV typing using polymerase chain reaction techniques and in situ hybridization. Staging of disease severity was performed in real time at each endoscopic procedure using an RRP scoring system developed by one of the authors (B.J.W.). The frequency of endoscopic operative debridement was recorded for each patient. Information in the database was analyzed to identify statistically significant relationships between extent of disease and/or HPV type, patient age at diagnosis, and selected epidemiological factors.
RESULTS: The study may represent the first longitudinal prospective analysis of a large pediatric RRP population. Fifty-eight of the 73 patients in the study underwent HPV typing. Patients infected with HPV-11 were significantly more likely to have higher severity scores, require more frequent surgical intervention, and require adjuvant therapy to control disease progression. In addition, patients with HPV-11 RRP were significantly more likely to develop tracheal disease, to require tracheotomy, and to develop pulmonary disease. Patients receiving a diagnosis of RRP before 3 years of age had significantly higher severity scores, higher frequencies of surgical intervention, and greater likelihood of requiring adjuvant medical therapy. Patients with Medicaid insurance had significantly higher severity scores and required more frequent surgical debridement. Birth by cesarean section appeared to be a significant risk factor for more severe disease and necessity of more frequent surgical intervention.
CONCLUSION: Statistical analysis of the relationships among epidemiological factors, HPV type, and clinical course revealed that patients with HPV-11 and patients younger than 3 years of age at RRP diagnosis are prone to develop more aggressive disease as represented by higher severity scores at endoscopic debridement, more frequent operative debridement procedures per year, a greater requirement for adjuvant therapy, and greater likelihood of tracheal disease with tracheotomy.

Entities:  

Mesh:

Year:  2004        PMID: 15514560     DOI: 10.1097/01.mlg.000148224.83491.0f

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  43 in total

1.  Bronchiolar Adenoma: Expansion of the Concept of Ciliated Muconodular Papillary Tumors With Proposal for Revised Terminology Based on Morphologic, Immunophenotypic, and Genomic Analysis of 25 Cases.

Authors:  Jason C Chang; Joseph Montecalvo; Laetitia Borsu; Shaohua Lu; Brandon T Larsen; William Dean Wallace; Wichit Sae-Ow; Alexander C Mackinnon; Hyunjae R Kim; Anita Bowman; Jennifer L Sauter; Maria E Arcila; Marc Ladanyi; William D Travis; Natasha Rekhtman
Journal:  Am J Surg Pathol       Date:  2018-08       Impact factor: 6.394

2.  Human papillomavirus vaccine policies among american Indian tribes in Washington State.

Authors:  Jessie Duvall; Dedra Buchwald
Journal:  J Pediatr Adolesc Gynecol       Date:  2012-01-20       Impact factor: 1.814

3.  Use of cidofovir in HPV patients with recurrent respiratory papillomatosis.

Authors:  M Grasso; M Remacle; V Bachy; S Van Der Vorst; G Lawson
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-04-23       Impact factor: 2.503

4.  Pharyngeal squamous cell papilloma in adult Japanese: comparison with laryngeal papilloma in clinical manifestations and HPV infection.

Authors:  Ryoji Hirai; Kiyoshi Makiyama; Yusho Higuti; Atsuo Ikeda; Masatoshi Miura; Hisashi Hasegawa; Noriko Kinukawa; Minoru Ikeda
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-01-04       Impact factor: 2.503

5.  In situ hybridization signal patterns in recurrent laryngeal squamous papillomas indicate that HPV integration occurs at an early stage.

Authors:  Erin Grace Brooks; Mark Francis Evans; Christine Stewart-Crawford Adamson; Zhihua Peng; Vanitha Rajendran; Rodolfo Laucirica; Kumarasen Cooper
Journal:  Head Neck Pathol       Date:  2011-11-05

6.  Novel human papilloma virus (HPV) genotypes in children with recurrent respiratory papillomatosis.

Authors:  Ioannis N Mammas; George Sourvinos; Elena Vakonaki; Panagiota Giamarelou; Catherine Michael; Demetrios A Spandidos
Journal:  Eur J Pediatr       Date:  2010-03-07       Impact factor: 3.183

Review 7.  Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.

Authors:  Ralph P Insinga; Erik J Dasbach; Elamin H Elbasha
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

8.  Clinical Activity of Nivolumab for Human Papilloma Virus-Related Juvenile-Onset Recurrent Respiratory Papillomatosis.

Authors:  Ben C Creelan; M Usman Ahmad; Frank J Kaszuba; Farah K Khalil; Allison W Welsh; Metin Ozdemirli; Nazaneen N Grant; Deepa S Subramaniam
Journal:  Oncologist       Date:  2019-03-06

9.  Human papilloma virus vaccination in patients with an aggressive course of recurrent respiratory papillomatosis.

Authors:  Irena Hočevar-Boltežar; Mojca Matičič; Maja Sereg-Bahar; Nina Gale; Mario Poljak; Boštjan Kocjan; Miha Zargi
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-26       Impact factor: 2.503

10.  Safety of intralesional cidofovir in patients with recurrent respiratory papillomatosis: an international retrospective study on 635 RRP patients.

Authors:  R E A Tjon Pian Gi; T Ilmarinen; E R van den Heuvel; L M Aaltonen; J Andersen; J W Brunings; M Chirila; A Dietz; F Ferran Vilà; G Friedrich; H H W de Gier; W Golusinski; M Graupp; A Hantzakos; R Horcasitas; J Jackowska; J C Koelmel; G Lawson; F Lindner; M Remacle; C Sittel; V Weichbold; M Wierzbicka; F G Dikkers
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-02-03       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.